Clinical review 124: Diabetic dyslipidemia: causes and consequences.
about
Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acidEffects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patientsLipoprotein(a): an independent risk factor for ischemic heart disease that is dependent on triglycerides in subjects with type 2 diabetes mellitusHelicobacter pylori infection and diabetes: is it a myth or fact?Diabetic cardiovascular disease: getting to the heart of the matter.Correlation between hemoglobin A1c and serum lipid profile in Afghani patients with type 2 diabetes: hemoglobin A1c prognosticates dyslipidemia.The LDL Receptor-Related Protein 1: At the Crossroads of Lipoprotein Metabolism and Insulin SignalingThe prevalence of dyslipidemia in patients with diabetes mellitus of ayurveda HospitalSerum IL-17, IL-23, and TGF-β levels in type 1 and type 2 diabetic patients and age-matched healthy controlsControlling Lipids AIDS in the Prevention of Type 2 Diabetes, Hypertension, and Cardiovascular Diseases.Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.Diabetes in relation to biliary tract cancer and stones: a population-based study in Shanghai, ChinaPeroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) stimulates VLDL assembly through activation of cell death-inducing DFFA-like effector B (CideB)Urban-rural differences in atherogenic dyslipidaemia (URDAD Study): a retrospective report on diabetic and non-diabetic subjects of Northern India.A lipasin/Angptl8 monoclonal antibody lowers mouse serum triglycerides involving increased postprandial activity of the cardiac lipoprotein lipase.Lipoprotein (a) and atherogenic indices in Sudanese patients with type 2 diabetes.Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional studyAdditive effects of postchallenge hyperglycemia and low-density lipoprotein particles on the risk of arterial stiffness in healthy adults.HPLC-DAD Analysis and In-Vitro Property of Polyphenols Extracts from (Solanum Aethiopium) Fruits on α -Amylase, α -Glucosidase and Angiotensin - 1- Converting Enzyme Activities.The association between the apolipoprotein A1/ high density lipoprotein -cholesterol and diabetes in Taiwan - a cross-sectional studyEffects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis.Lipid profile of type 2 diabetic and hypertensive patients in the jamaican population.Prevalences of overweight, obesity, hyperglycaemia, hypertension and dyslipidaemia in the Gulf: systematic review.Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor.Development of a nongenetic mouse model of type 2 diabetes.Impact of corpulence parameters and haemoglobin A1c on metabolic control in type 2 diabetic patients: comparison of apolipoprotein B/A-I ratio with fasting and postprandial conventional lipid ratiosClinical applications of advanced lipoprotein testing in diabetes mellitusSystemic alterations in the metabolome of diabetic NOD mice delineate increased oxidative stress accompanied by reduced inflammation and hypertriglyceremiaDifferential response in levels of high-density lipoprotein cholesterol to one-year metformin treatment in prediabetic patients by race/ethnicity.Diabetes-specific nutrition algorithm: a transcultural program to optimize diabetes and prediabetes care.Serum lipids and associated factors of dyslipidemia in the adult population in Shenzhen.Lipid Profiles and Serum Visfatin Concentrations in Patients with Type II Diabetes in Comparison with Healthy Controls.Fatty liver in men is associated with high serum levels of small, dense low-density lipoprotein cholesterol.Cardiovascular diseases risk evaluation in newly diagnosed type-2 diabetics: An association of novel biomarkers apo proteins and C-peptide.Diabetes and dyslipidaemia.Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS studyDiabetic atherosclerosis in APOE*4 mice: synergy between lipoprotein metabolism and vascular inflammationComparative study on the effects of type 1 and type 2 diabetes on structural changes and hormonal output of the adrenal cortex in male Wistar ratsActivation of peroxisome proliferator activated receptor-gamma results in an atheroprotective apolipoprotein profile in HepG2 cells.Examining the role of lipid mediators in diabetic retinopathy.
P2860
Q24594113-08A2D559-BAD8-4D90-8173-786D94ED771CQ24634840-97475AA1-B6DB-4629-9DE2-4C3C79820D71Q28222400-2E15F0FC-18BC-46F6-9F9C-25FAAB3D6A6CQ30361927-B39FBEFE-5793-4690-9E8E-04D0C09D7847Q30451529-C6179A10-FBC9-4872-84FB-6B4FAA52DEF6Q33632376-D46227E2-057C-4AB0-8FDF-509CAC74BC67Q33726334-766B27F7-A092-4601-963C-31677C79098CQ33732068-64449D44-5F4E-4BFF-AD01-E847DE30D7F4Q33786938-CF554A35-4869-42B5-B422-B123448EFB25Q33810532-24AF9D65-093C-444F-994A-5CD4F837AE7CQ33887783-2591D87A-A987-4406-86D4-44C4E15A5BF8Q34000282-E5E332E4-6E78-423A-8F59-A78ED27A6E05Q34074263-DC230DBE-957E-44FD-992A-8A168EE5775CQ34458547-9EE14924-DF20-47DE-AC85-8F7CE215D754Q34505898-1831C712-5616-478D-BEAA-11B433CC83AFQ34638701-622C7B77-1FF9-427F-B3BB-378927E76A30Q34740328-0A4E4D8A-FE4A-42A5-9530-210C3C716754Q34793839-314651EA-2159-4293-875C-30BF94688CD4Q34903306-D6912F3A-513E-4C34-AF03-8C0A9ED18902Q35008066-46FA1B5C-0048-4E2E-B738-2E2C049822E4Q35043813-D801536F-C8D0-47EA-B9E8-C5A68E59ADD7Q35137994-A155DF17-DE67-4267-8588-FA477B4B0868Q35138369-42D8BD35-DA6E-47A3-8F49-601310CC0F96Q35179999-4BF64F71-1896-4A42-B387-9C05A3F73AF8Q35580004-BA4910A1-BBBA-4BE1-BC9F-0AC7476B9DB1Q35589699-7893A1C3-3E4C-4CEF-AD6A-73467C161E8DQ35598303-99F4A3F2-3111-455D-9CFB-3290C59CAE1FQ35671693-225F41BE-00EA-44D2-B7AE-9914041782D0Q35736638-3E86756B-53F2-4EBB-9D97-79AE9E72BD6CQ35828239-8DF8976A-FFB9-4075-A66C-74BE4358B83FQ35848122-F829A975-72C4-4818-83DE-B7DD9118BAA1Q36022762-5BBE9C6E-F669-4279-A416-89CE303DD23FQ36278478-91B040C4-7C61-4F45-830A-9232FBE14B1AQ36436458-3DF47117-D4B5-468B-AB71-236D349C0E76Q36507637-B98C385D-AD13-4EF4-BD1E-38CE1D2A3AA7Q36536280-B6F0FBA2-5708-40A4-B197-C885ABD30CB8Q36658372-361AC857-A545-4801-B6FD-99759603EF0BQ36686384-72ED7B16-FAE7-4243-A5D8-7B0D86737D4EQ36783555-0C2CC6AC-3D5B-4AD8-82DF-420575823DC2Q36808421-9BF3F85E-DA19-4BF3-935A-18D5E5C9C886
P2860
Clinical review 124: Diabetic dyslipidemia: causes and consequences.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Clinical review 124: Diabetic dyslipidemia: causes and consequences.
@ast
Clinical review 124: Diabetic dyslipidemia: causes and consequences.
@en
Clinical review 124: Diabetic dyslipidemia: causes and consequences.
@nl
type
label
Clinical review 124: Diabetic dyslipidemia: causes and consequences.
@ast
Clinical review 124: Diabetic dyslipidemia: causes and consequences.
@en
Clinical review 124: Diabetic dyslipidemia: causes and consequences.
@nl
prefLabel
Clinical review 124: Diabetic dyslipidemia: causes and consequences.
@ast
Clinical review 124: Diabetic dyslipidemia: causes and consequences.
@en
Clinical review 124: Diabetic dyslipidemia: causes and consequences.
@nl
P356
P1476
Clinical review 124: Diabetic dyslipidemia: causes and consequences.
@en
P2093
Goldberg IJ
P304
P356
10.1210/JC.86.3.965
P407
P577
2001-03-01T00:00:00Z